Skip to Content

ESG Industry Landscape Report: Biopharma

The United States dominates global drug sales and profits. The region also has prices roughly twice as high as other major developed markets. When does drug pricing become an investment risk?

Our new landscape report covers material ESG issues for biotechnology, drug manufacturers, or pharmaceuticals. We explore ESG trends in the pharmaceutical industry that could affect shareholder value.

Share this page

Research Library ESG Industry Landscape Report: Biopharma

What's Inside:

  • The top three material ESG risks faced by pharma and biotech (biopharma) firms.
  • A review of our ranking system for drug pricing risk.
  • Two undervalued stock picks.

Get the Report